infection-congress-2017-scientifictracks-abstracts

10 / 17

Page 36
Notes:
conferenceseries.com
Volume 5, Issue 2 (Suppl) J Infect Dis Ther 2017
ISSN: 2332-0877, JIDT an open access journal Infection Congress 2017
May 11-12, 2017
May 11-12, 2017 Barcelona, Spain
4th International Congress on
Infectious Diseases
Ashok Rattan et al., J Infect Dis Ther 2017, 5:2 (Suppl)
Nitrofurantoin sensitivity pattern for uropathogens pan India
The prevalence of urinary tract infections (UTIs) varies from 21.8% to 31.3% in various parts of the country. The most common
pathogens causing UTIs in the descending order of their prevalence include Escherichia coli (45.12%), Klebsiella spp. (18.17%)
and Enterococcus spp. (9.23%). Nitrofurantoin was categorized as an A-I antibiotic for treating UTIs as per the IDSA guidelines,
while nitrofurantoin 100 mg tablet dosage form was added to the WHO model list of essential medicines since 2013. The major
strength of nitrofurantoin is its action at multiple sites and levels which helped the drug to maintain an excellent level of sensitivity
over six decades of clinical practice besides being well tolerated for treating acute uncomplicated cystitis. In this review, we analyze,
from all the recent accessible and available clinical studies, nitrofurantoin sensitivity pattern across various parts of India, while also
comparing it with the sensitivity of other commonly used antimicrobials. We have found that not only nitrofurantoin has retained
excellent sensitivity to the most common uropathogens across India, but also stands out to be the antimicrobial of choice when
considering other parameters like oral route of administration, safety profile and cost-effectiveness in the management of UTIs..
Biography
Ashok Rattan has expertise in Microbiology, Immunogenetics and Molecular Biology and holds important positions in academics (JN Medical College, Aligarh;
AIIMS, New Delhi; Sharjah Medical College and Mahatma Gandhi Medical University, Jaipur); in industrial research (Ranbaxy New Drug Discovery and Fortis
Clinical Research Ltd) and in Diagnostic labs (Religare SRL Diagnostics and Star Metropolis). He has published over 100 research papers in peer reviewed in-
ternational journals. He has contributed more than a dozen chapters in different books and has conducted workshops on WHONET in all nine SEARO countries..
Ashok Rattan
Pathkind Diagnostics Pvt Ltd, New Delhi, India